⌘K
t
| TIDM | AMS |
| Share Price | 280.00p-0.53% |
| Market Cap | £614.89m |
| Date | 4 Nov 2021 |
| Time | 07:00:05 |
| Category | Corporate updates |
| ID | 2813R |
04 November 2021
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Appointment of Adviser
Winsford, UK: Advanced Medical Solutions plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces the appointment of HSBC Bank plc ("HSBC") as its Joint Broker and Joint Financial Adviser, with immediate effect. Investec Bank plc will continue to act as Nominated Adviser, Joint Broker and Joint Financial Adviser to the Company.
- End -
For further information, please contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations Manager |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Matthew Cole |
|
|
|
|
|
Investec Bank plc - Nominated Adviser, Joint Broker and Joint Financial Adviser |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Gary Clarence |
|
|
HSBC Bank plc - Joint Broker and Joint Financial Adviser |
Tel: 44 (0)20 7991 8888 |
|
Sam McLennan / Joe Weaving |
|
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.